ERBB2 and breast carcinoma: In many countries, immunohistochemistry-based assessment of Ki67 is part of the routine biomarker evaluation of breast cancers along with estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2).